Our Experience

Our staff have considerable experience in clinical trial projects. Here is a cross section of projects:

A Phase II, Global, Non-Randomized, Placebo Controlled, 54 Patient, Study of the Safety and Clinical Pharmacology of Stanate® in Infants at-Risk for Exchange Transfusion
A Phase III, open label program of Adefovir Dipivoxil in the treatment of patients with Lamuvidine-resistant chronic hepatitis B who have limited treatment options.
Peg-Intron plus Rebetrol for the treatment of subjects with Chronic Hepatitis C who failed to respond to previous combination therapy (any alpha-interferon treatment in combination with Ribavirin).
Pegylated Interferon (PEG IFN) and Lamuvidine combination in patients with chronic HBV infection.
A phase III partially double blind study evaluating the efficacy and safety of a 40kD-branched pegylated interferon alpha-2a (PEG IFN, Ro 25-8310) combined with placebo or lamuvidine versus lamuvidine in HBeAg positive patients with chronic hepatitis B.
Extended (48 weeks) treatment with Rebetron multi-dose pen in previously untreated chronic hepatitis C patients with genotype 2 or 3.
Comparison PEG Interferon alpha-2b + Ribavirin vs. Interferon alpha-2b + Ribavirin for the treatment of Hepatitis C.
Multi-Center Open Label Expanded Access program of Peg-Interferon alpha-2a (Ro 25-8310) Monotherapy and Combination therapy with Ribavirin (Ro-9963) in patients with chronic hepatitis C.
Immunotherapy with novel hepatitis B vaccine as potential treatment for chronic active hepatitis B.
Long term follow-up protocol to asses subjects after completing 24 weeks follow up in SPRI clinical trial for the treatment of Chronic Hepatitis C.
An extension protocol to evaluate the long term effect of treatment with Peg-Interferon alpha-2 (Peg-IFN) or Roferon-A for patients with chronic hepatitis C